ALPMY:OTC-Astellas Pharma Inc (USD)

COMMON STOCK | Drug Manufacturers-General | OTC

Last Closing Price

USD 17.35

Change

0.00 (0.00)%

Market Cap

USD 32.63B

Volume

0.04M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
RHHBF Roche Holding AG

N/A

USD333.79B 22.88 14.34
RHHBY Roche Holding AG

N/A

USD328.85B 20.48 14.62
RHHVF Roche Holding AG

N/A

USD326.90B 20.44 14.34
NVSEF Novartis AG

N/A

USD210.90B 26.74 14.23
AZNCF AstraZeneca PLC

N/A

USD151.86B 38.17 18.77
SNYNF Sanofi

N/A

USD132.85B 9.05 9.08
GLAXF GlaxoSmithKline plc

N/A

USD100.43B 13.60 13.19
CHGCF Chugai Pharmaceutical Co., Ltd

N/A

USD66.41B 34.95 0.21
CHGCY Chugai Pharmaceutical Co., Ltd

N/A

USD64.21B 33.79 0.21
BAYZF Bayer Aktiengesellschaft

N/A

USD62.55B 8.75 10.06

ETFs Containing ALPMY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.37% 76% C 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.37% 71% C- 43% F
Trailing 12 Months  
Capital Gain 5.66% 74% C 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.66% 71% C- 24% F
Trailing 5 Years  
Capital Gain 13.25% 47% F 44% F
Dividend Return 0.97% 31% F 8% F
Total Return 14.22% 43% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 3.73% 36% F 37% F
Dividend Return 0.06% 16% F 8% F
Total Return 3.79% 28% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 16.14% 72% C- 87% B+
Risk Adjusted Return 23.49% 33% F 46% F
Market Capitalization 32.63B 63% D 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.46 30% F 27% F
Price/Book Ratio 2.55 65% D 42% F
Price / Cash Flow Ratio 0.11 77% C+ 48% F
EV/EBITDA 0.12 81% B- 80% B-
Management Effectiveness  
Return on Equity 9.02% 44% F 68% D+
Return on Invested Capital -3.84% 14% F 35% F
Return on Assets 6.11% 62% D- 87% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.63 34% F 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.